MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ajpc.2026.101426

Медицинская библиотека · American journal of preventive cardiology · 2026

Cardioprotective therapy in type 2 diabetes guided by a proteomic risk model: A randomized trial.

Gill Rosalynn, Carpenter Meredith A, Holstein Amy, Garcia Ariadne Reyes, Alkholder Ayman, Gupta Aanchal, Singh Vatsala, Quyyumi Arshed A, Rasouli Neda, Neeland Ian J, Williams Stephen A

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Cardioprotective (CP) therapies such as GLP-1 RA, SGLT2i, and PCSK9i medications remain underutilized in cardiovascular (CV) risk management. Individualized risk assessment using blood-based proteomic testing, such as Residual Cardiovascular Risk (RCVR) scores, may help guide treatment decisions.

OBJECTIVE

To evaluate whether access to RCVR scores improves risk-concordant prescribing of CP medications in clinical practice.

METHODS

In this multicenter, open label, behavioral randomized trial, adults with type 2 diabetes eligible for CP medications underwent SomaScan™ proteomic testing. Participants were randomized to an informed (RCVR results shared with patient and clinicians) or uninformed arm (results withheld until study end). CP prescribing rate and sensitivity-to-change of RCVR to CP initiation were assessed by trial arm. Chi-square trend in proportions, one-sided 2-sample tests for equality of proportions, and one-sided paired Wilcoxon signed-rank tests were used for statistical analysis.

RESULTS

Among 377 baseline participants analyzed (59 % informed; mean age 66 ± 10.3 years; 45 % female), CP prescribing was significantly higher in the informed versus uninformed arm (32.1 % vs 9.6 %; OR 5.45; 95 % CI: 2.31-12.89; p < 0.001); per-risk-bin rates were also significantly higher in all elevated risk bins (p<0.05). Among 173 participants with paired RCVR scores from baseline-6-months, CP initiation (n = 24) in the informed arm (n = 92) corresponded to a 3.9 % reduction in proteomic-predicted CV risk (p = 0.036).

CONCLUSIONS

Disclosure of proteomic RCVR scores was associated with higher rates of CP prescribing and short-term reductions in proteomic risk scores among CP medication users; proteomics-based risk assessment may support personalized CV prevention.

Для цитирования: Gill Rosalynn, Carpenter Meredith A, Holstein Amy, Garcia Ariadne Reyes, Alkholder Ayman, Gupta Aanchal, Singh Vatsala, Quyyumi Arshed A, Rasouli Neda, Neeland Ian J, Williams Stephen A. Cardioprotective therapy in type 2 diabetes guided by a proteomic risk model: A randomized trial.. American journal of preventive cardiology. 2026. DOI: 10.1016/j.ajpc.2026.101426.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.